University Hospital, Linköping, Sweden.
Gastrointest Endosc. 2010 Nov;72(5):915-23. doi: 10.1016/j.gie.2010.07.036.
Covered biliary metal stents have been developed to prevent tumor ingrowth. Previous comparative studies are limited and often include few patients.
To compare differences in stent patency, patient survival, and complication rates between covered and uncovered nitinol stents in patients with malignant biliary obstruction.
Randomized, multicenter trial conducted between January 2006 and October 2008.
Ten sites serving a total catchment area of approximately 2.8 million inhabitants.
A total of 400 patients with unresectable distal malignant biliary obstruction.
ERCP with insertion of covered or uncovered metal stent. Follow-up conducted monthly for symptoms indicating stent obstruction.
Time to stent failure, survival time, and complication rate.
The patient survival times were 116 days (interquartile range 242 days) and 174 days (interquartile range 284 days) in the covered and uncovered stent groups, respectively (P = .320). The first quartile stent patency time was 154 days in the covered stent group and 199 days in the uncovered stent group (P = .326). There was no difference in the incidence of pancreatitis or cholecystitis between the 2 groups. Stent migration occurred in 6 patients (3%) in the covered group and in no patients in the uncovered group (P = .030).
Randomization was not blinded.
There were no significant differences in stent patency time, patient survival time, or complication rates between covered and uncovered nitinol metal stents in the palliative treatment of malignant distal biliary obstruction. However, covered stents migrated significantly more often compared with uncovered stents, and tumor ingrowth was more frequent in uncovered stents.
带膜胆道金属支架的开发是为了防止肿瘤向内生长。以前的比较研究有限,且通常纳入的患者较少。
比较带膜和无膜镍钛合金支架在治疗恶性胆道梗阻患者中的支架通畅率、患者生存率和并发症发生率的差异。
2006 年 1 月至 2008 年 10 月进行的随机、多中心试验。
为大约 280 万居民服务的 10 个地点。
共 400 例不可切除的远端恶性胆道梗阻患者。
经内镜逆行胰胆管造影术(ERCP)并插入带膜或无膜金属支架。每月对出现支架阻塞症状的患者进行随访。
支架失效时间、生存时间和并发症发生率。
带膜支架组和无膜支架组的患者生存率分别为 116 天(四分位距 242 天)和 174 天(四分位距 284 天)(P =.320)。带膜支架组的第一四分位支架通畅时间为 154 天,无膜支架组为 199 天(P =.326)。两组胰腺炎和胆囊炎的发生率无差异。带膜支架组有 6 例(3%)患者发生支架迁移,无膜支架组无患者发生支架迁移(P =.030)。
随机分组未设盲。
在姑息治疗恶性远端胆道梗阻中,带膜和无膜镍钛合金金属支架在支架通畅时间、患者生存时间或并发症发生率方面无显著差异。然而,与无膜支架相比,带膜支架的迁移发生率明显更高,且无膜支架的肿瘤内生长更为常见。